870 related articles for article (PubMed ID: 22745561)
1. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Volpe M; Tocci G
Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
da Silva PM
Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
[TBL] [Abstract][Full Text] [Related]
3. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
[TBL] [Abstract][Full Text] [Related]
4. Olmesartan/amlodipine: a review of its use in the management of hypertension.
Kreutz R
Vasc Health Risk Manag; 2011; 7():183-92. PubMed ID: 21490944
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
6. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
Schmieder RE
Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
[TBL] [Abstract][Full Text] [Related]
7. Treating essential hypertension. The first choice is usually a thiazide diuretic.
Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.
de la Sierra A; Barrios V
Adv Ther; 2012 May; 29(5):401-15. PubMed ID: 22610686
[TBL] [Abstract][Full Text] [Related]
9. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
10. Hypertension management: rationale for triple therapy based on mechanisms of action.
Neutel JM; Smith DH
Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
Rump LC; Sellin L
Expert Opin Pharmacother; 2010 Sep; 11(13):2231-42. PubMed ID: 20707758
[TBL] [Abstract][Full Text] [Related]
12. Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform.
Volpe M; Tocci G; de la Sierra A; Kreutz R; Laurent S; Manolis AJ; Tsioufis K
High Blood Press Cardiovasc Prev; 2017 Dec; 24(4):463-472. PubMed ID: 29086364
[TBL] [Abstract][Full Text] [Related]
13. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
Tocci G; Paneni F; Passerini J; Volpe M
Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.
Ruilope LM
Vasc Health Risk Manag; 2008; 4(6):1237-48. PubMed ID: 19337537
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
[TBL] [Abstract][Full Text] [Related]
16. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
Omboni S; Kario K; Bakris G; Parati G
J Hypertens; 2018 Apr; 36(4):720-733. PubMed ID: 29045341
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis.
Kizilirmak P; Berktas M; Uresin Y; Yildiz OB
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):193-200. PubMed ID: 23458592
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
[TBL] [Abstract][Full Text] [Related]
19. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients.
Volpe M; de la Sierra A; Kreutz R; Laurent S; Manolis AJ
High Blood Press Cardiovasc Prev; 2014 Jun; 21(2):137-47. PubMed ID: 24532183
[TBL] [Abstract][Full Text] [Related]
20. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
Mengden T; Uen S; Bramlage P
Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
